acalabrutinib

Ukraine

Drugs containing this active substance

  • CALQUENS

    The drug is intended for the treatment of adult patients with chronic lymphocytic leukemia (CLL). It may be used either as monotherapy or in combination with obinutuzumab (if the disease has not been previously treated), or as monotherapy (if the patient has already undergone previous courses of treatment).

    Form: capsules, hard

    Active substance Dosage
    acalabrutinib 100 mg

    ATC: L01EL02

    Manufacturer: AstraZeneca AB (manufacturing, quality control, primary and secondary packaging, batch release)

  • CALQUENS

    The drug is intended for the treatment of adult patients with chronic lymphocytic leukemia (CLL). It may be used as monotherapy or in combination with obinutuzumab, depending on whether the patient has received prior treatment.

    Form: tablets, film-coated

    Active substance Dosage
    acalabrutinib 100 mg

    ATC: L01EL02

    Manufacturer: AstraZeneca AB (manufacturing, quality control, primary and secondary packaging, batch release; quality control)